| |
Controls (n = 186)
|
CHD group (n = 264)
|
|---|
|
Before treatment
|
After treatment
|
|---|
|
TG (mmol/l)
|
1.15 ± 0.35
|
1.58 ± 0.58*
|
1.14 ± 0.71§
|
|
TC (mmol/l)
|
4.11 ± 0.37
|
5.14 ± 0.49*
|
4.35 ± 0.53§
|
|
HDL-C (mmol/L)
|
1.37 ± 0.31
|
1.10 ± 0.25*
|
1.29 ± 0.27§
|
|
LDL-C (mmol/L)
|
2.00 ± 0.51
|
3.1 ± 0.27*
|
2.32 ± 0.30§
|
|
VLDL-C (mmol/L)
|
0.75 ± 0.21
|
1.03 ± 0.24*
|
0.78 ± 0.16§
|
|
MMP-9 (ng/ml)
|
40.78 ± 9.72
|
78.17 ± 21.43*
|
60.32 ± 20.30§
|
|
TNF-α (pg/ml)
|
81.23 ± 39.07
|
136.95 ± 52.41*
|
102.37 ± 47.19§
|
|
IL-10 (pg/ml)
|
32.18 ± 12.15
|
98.65 ± 34.79*
|
50.31 ± 24.28§
|
- Values are expressed as mean ± SD. Comparison between controls and CHD subjects were by unpaired student T-test; comparison between before and after treatment of statin were by paired student T-test. *P <0.0001 compared with control group; §
P <0.0001 compared with before treatment. CHD coronary heart disease, MMP9 matrix metalloproteinase 9, IL-10 interleukin-10, TNF-α TNF-alpha, TC total cholesterol, TG triglyceride, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol, VLDL-C very low density lipoprotein cholesterol
